No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study

SIMPLE SUMMARY: Neuroblastoma RAS Viral Oncogen Homolog (NRAS) mutant melanoma is usually considered more aggressive and more responsive to checkpoint inhibitor immunotherapy (CII) than NRAS wildtype. We retrospectively recruited 331 metastatic melanoma patients treated with CII as first line: 162 N...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Guida, Michele, Bartolomeo, Nicola, Quaglino, Pietro, Madonna, Gabriele, Pigozzo, Jacopo, Di Giacomo, Anna M., Minisini, Alessandro M., Tucci, Marco, Spagnolo, Francesco, Occelli, Marcella, Ridolfi, Laura, Queirolo, Paola, De Risi, Ivana, Quaresmini, Davide, Gambale, Elisabetta, Chiaron Sileni, Vanna, Ascierto, Paolo A., Stigliano, Lucia, Strippoli, Sabino
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7865301/
https://ncbi.nlm.nih.gov/pubmed/33530579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13030475
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars